iBio and AstralBio Provide Update on Myostatin Program for Obesity
iBio, Inc. (IBIO)
NASDAQ:AMEX Investor Relations:
ir.ibioinc.com
Company Research
Source: GlobeNewswire
SAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for cardiometabolic disease and obesity in collaboration with AstralBio. iBio’s technology stack enabled the Company to rapidly advance the joint myostatin program from inception to in vitro proof-of-concept in human muscle cells. Following early discovery, the companies have identified a molecule with therapeutic potential for treating muscle wasting and obesity, which is designed for subcutaneous administration and has potential for an extended half-life. The companies are currently working on plans to advance this molecule into non-cGMP in vivo studies in rodents and non-human primates (NHP) with potential early readouts of the NHP in early 2025. "Myostatin inhibitors hold great promise for treating obesity and cardiometabolic diseases by increasing muscle mass and boosting metabolism," said Martin B
Show less
Read more
Impact Snapshot
Event Time:
IBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IBIO alerts
High impacting iBio, Inc. news events
Weekly update
A roundup of the hottest topics
IBIO
News
- iBio Strengthens Board with Appointment of Two New Independent Directors [Yahoo! Finance]Yahoo! Finance
- iBio Strengthens Board with Appointment of Two New Independent DirectorsGlobeNewswire
- AiAdvertising Announces CFO Transition in Preparation for Nasdaq Uplisting [Yahoo! Finance]Yahoo! Finance
- iBio Reports Fiscal First Quarter 2025 Financial ResultsGlobeNewswire
IBIO
Sec Filings
- 12/9/24 - Form 4
- 12/9/24 - Form 3
- 11/25/24 - Form 4
- IBIO's page on the SEC website